We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+14.89%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
+$163M
Cap. Flow
-$639M
Cap. Flow %
-24.64%
Top 10 Hldgs %
35.1%
Holding
118
New
11
Increased
13
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$84.6M
2
MCK icon
McKesson
MCK
+$33.5M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$32.2M
4
LOXO
Loxo Oncology, Inc
LOXO
+$20.7M
5
BHC icon
Bausch Health
BHC
+$20.6M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$102M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$61.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$46.5M
4
NVRO
NEVRO CORP.
NVRO
+$31.5M
5
HUM icon
Humana
HUM
+$26.6M

Sector Composition

Rank Sector Weight
1 Healthcare 71.12%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
51
DELISTED
Array Biopharma Inc
ARRY
$10.2M 0.39%
1,142,744
-507,256
-31% -$5.4M
STDY
52
DELISTED
SteadyMed Ltd
STDY
$10.2M 0.39%
1,756,370
– –
TSRO
53
DELISTED
TESARO, Inc.
TSRO
$10.2M 0.39%
66,000
-46,200
-41% -$7.52M
BLUE
54
DELISTED
bluebird bio
BLUE
$9.73M 0.38%
8,265
-15,051
-65% -$15.4M
OXFD
55
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$9.55M 0.37%
616,508
+87,311
+16% +$1.25M
DXCM icon
56
DexCom
DXCM
$29.6B
$9.4M 0.36%
+443,968
New +$8.67M
GKOS icon
57
Glaukos
GKOS
$9.21B
$9.23M 0.36%
180,000
-213,228
-54% -$9.29M
GMED icon
58
Globus Medical
GMED
$10.5B
$9.12M 0.35%
308,000
-728,000
-70% -$19.9M
SAGE
59
DELISTED
Sage Therapeutics
SAGE
$8.67M 0.33%
+122,000
New +$7.15M
SIOX
60
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.49M 0.33%
71,001
– –
MYOV
61
DELISTED
Myovant Sciences Ltd.
MYOV
$8.28M 0.32%
705,268
-791,407
-53% -$9.07M
ALIM
62
DELISTED
Alimera Sciences
ALIM
$8.23M 0.32%
391,868
– –
TGTX icon
63
TG Therapeutics
TGTX
$8.4B
$8.15M 0.31%
+700,000
New +$5.02M
SRRA
64
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$7.61M 0.29%
124,308
+95,143
+326% +$5.53M
NSTG
65
DELISTED
NanoString Technologies, Inc.
NSTG
$7M 0.27%
352,375
+213,375
+154% +$4.06M
EPIX
66
DELISTED
ESSA Pharma
EPIX
$6.62M 0.26%
106,080
– –
INFI
67
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$6.36M 0.25%
+1,969,225
New +$4.84M
KITE
68
DELISTED
Kite Pharma, Inc.
KITE
$6.36M 0.25%
81,000
-216,902
-73% -$13.4M
MYOK
69
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.59M 0.22%
424,800
– –
ZVRA icon
70
Zevra Therapeutics
ZVRA
$755M
$5.31M 0.2%
67,778
– –
FPRX
71
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$4.99M 0.19%
138,000
– –
SGMO
72
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.36M 0.17%
837,963
– –
FOMX
73
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.05M 0.16%
817,435
-415,409
-34% -$4M
RARX
74
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.79M 0.15%
177,830
-145,800
-45% -$2.79M
ARLZ
75
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$3.52M 0.14%
1,644,583
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2017 Portfolio in Review

As of Q1 2017, Deerfield Management held 118 positions worth $2.59B, up 6.7% from $2.43B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $639M in Q1 2017, closing 12 positions and reducing 28 holdings. Its most notable exit was Zimmer Biomet, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 69% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Gilead Sciences worth $81.7M.

  • Deerfield Management's largest Q1 2017 buy was Gilead Sciences: 1,203,000 shares worth $81.7M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $32.2M increase.
  • Deerfield Management's biggest Q1 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $102M.
  • Deerfield Management fully exited Zimmer Biomet in Q1 2017, selling an estimated $15.5M.
  • Deerfield Management's ten largest holdings make up 35% of its $2.59B portfolio in Q1 2017.
  • Deerfield Management opened 11 new positions and closed 12 in Q1 2017.
  • Deerfield Management's portfolio value rose 6.7% quarter-over-quarter to $2.59B.

Based on Deerfield Management's 13F filing for Q1 2017, filed 15 May 2017.